• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    The defects underlying impaired T-cell immunity in chronic lymphocytic leukaemia: the impact of lenalidomide 
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • The defects underlying impaired T-cell immunity in chronic lymphocytic leukaemia: the impact of lenalidomide
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • The defects underlying impaired T-cell immunity in chronic lymphocytic leukaemia: the impact of lenalidomide
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    The defects underlying impaired T-cell immunity in chronic lymphocytic leukaemia: the impact of lenalidomide

    View/Open
    John Riches PhD.pdf (7.197Mb)
    Publisher
    Queen Mary University of London
    Metadata
    Show full item record
    Abstract
    CLL T cells exhibit functional defects and alterations in gene expression that show similarities to exhausted T cells in chronic viral infections. It is unclear whether CLL T cells are truly exhausted, or whether these defects are restricted to expanded populations of CMV specific cells. The phenotype and function of T cells from CLL patients was compared to age- and CMV-serostatus-matched controls. There were an increased proportion of effector T cells in CLL patients and CMV-seropositive individuals. CD8+ and CD4+ T cells from CLL patients had increased expression of exhaustion markers CD160 and CD244 irrespective of CMV-serostatus, whereas increased PD1 expression on CD8+ T cells was limited to CMV-seronegative patients. CLL CD8+ T cells also showed defects in proliferation and cytotoxicity irrespective of CMV-serostatus, with the cytolytic defect caused by impaired granzyme packaging into vesicles and non-polarized degranulation. In contrast to virally-induced exhaustion, CLL T cells had increased expression of TBET and increased interferon-γ production, but normal IL-2 production. As lenalidomide repairs the functional and phenotypic defects associated with T-cell exhaustion, the effect of this agent on the gene expression profiles of lymphocyte subsets from CLL patients and healthy controls was investigated. Lenalidomide induced the expression of genes involved in cytoskeletal signalling, lymphocyte activation, and proliferation. In particular, lenalidomide up-regulated the expression of several genes involved in tight junction signalling, a pathway that is potentially involved in lymphocyte motility, immune synapse formation, and transendothelial migration. This pathway was down-regulated in T cells from CLL patients, but, intriguingly, was up-regulated in CLL cells compared with healthy B cells. This pathway is known to be negatively regulated by a phosphatase, PP2A. Treatment of CLL cells and T cells with the PP2A inhibitor okadaic acid mimicked the effect of lenalidomide. In conclusion, CLL T cells exhibit features of pseudo-exhaustion irrespective of CMV serostatus. Lenalidomide up-regulates tight junction signalling, which is down-regulated in CLL T cells. Inhibition of PP2A is implicated in the mechanism of action of lenalidomide on T cells.
    Authors
    Riches, John Charles
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/8446
    Collections
    • Theses [3834]
    Copyright statements
    The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.